News blog

Duke cancer trials allegedly lacked proper clearances.

“West_campus.jpg”After starting a misconduct investigation, suspending three clinical trials, and triggering an expensive Institute of Medicine (IOM) probe into the use of genomics technology in clinical trials, Duke University does not yet seem to be anyways near to moving on from the legal and ethical quagmire surrounding the work of cancer geneticist Anil Potti. 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE